Loading…
Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland
The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14...
Saved in:
Published in: | Acta Biochimica Polonica 2024-02, Vol.71 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | |
container_start_page | |
container_title | Acta Biochimica Polonica |
container_volume | 71 |
creator | Kondratiuk, Katarzyna Hallmann, Ewelina Szymański, Karol Łuniewska, Katarzyna Poznańska, Anna Brydak, Lidia B. |
description | The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14 years of age, 15–25 years of age, 26–44 years of age, 45–64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection. |
doi_str_mv | 10.3389/abp.2024.12289 |
format | article |
fullrecord | <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11077356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6f9e91a25bee4cecb0e4b7f946166117</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_11077356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-e4fbd57effb69d9ae07430bc2b64dde2a397ae53f6940435044fe5dc6831e4543</originalsourceid><addsrcrecordid>eNpVkMtKBDEQRYMoOI5uXfcP9JhHJT1ZiYgvEHSh4K6pJJU20pMe-jGgX2_ruHFTBfdcDkUxdi74Sqm1vUC3XUkuYSWkXNsDthCVglJoeDtkC865KLWs3o7ZyTB8cC6VsLBgu-eedthS9lR0sfCp91OLY8pNgXlMrguJhgIbTHkYi3faYNO008xT_umnHNuJ8hcWu9RPw1ydc9qmQJvki4Fw6HIxHyUu5iF_4HPXYg6n7ChiO9DZ316y19ubl-v78vHp7uH66rH0IORYEkQXdEUxOmODReIVKO68dAZCIInKVkhaRWOBg9IcIJIO3qyVINCgluxh7w0dftTbPm2w_6w7TPVv0PVNjf2YfEu1iZasQKkdEXjyjhO4Klowwhgx_3LJLveu7eQ2FDzlscf2n_Q_yem9brpdLQSvKqWN-gZI9YOp</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland</title><source>PubMed Central</source><creator>Kondratiuk, Katarzyna ; Hallmann, Ewelina ; Szymański, Karol ; Łuniewska, Katarzyna ; Poznańska, Anna ; Brydak, Lidia B.</creator><creatorcontrib>Kondratiuk, Katarzyna ; Hallmann, Ewelina ; Szymański, Karol ; Łuniewska, Katarzyna ; Poznańska, Anna ; Brydak, Lidia B.</creatorcontrib><description>The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14 years of age, 15–25 years of age, 26–44 years of age, 45–64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.</description><identifier>ISSN: 0001-527X</identifier><identifier>EISSN: 1734-154X</identifier><identifier>DOI: 10.3389/abp.2024.12289</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>GMT ; hemagglutinin antibodies ; influenza ; protection rate ; Science archive ; serum financial support</subject><ispartof>Acta Biochimica Polonica, 2024-02, Vol.71</ispartof><rights>Copyright © 2024 Kondratiuk, Hallmann, Szymański, Łuniewska, Poznańska and Brydak. 2024 Kondratiuk, Hallmann, Szymański, Łuniewska, Poznańska and Brydak</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077356/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077356/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Kondratiuk, Katarzyna</creatorcontrib><creatorcontrib>Hallmann, Ewelina</creatorcontrib><creatorcontrib>Szymański, Karol</creatorcontrib><creatorcontrib>Łuniewska, Katarzyna</creatorcontrib><creatorcontrib>Poznańska, Anna</creatorcontrib><creatorcontrib>Brydak, Lidia B.</creatorcontrib><title>Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland</title><title>Acta Biochimica Polonica</title><description>The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14 years of age, 15–25 years of age, 26–44 years of age, 45–64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.</description><subject>GMT</subject><subject>hemagglutinin antibodies</subject><subject>influenza</subject><subject>protection rate</subject><subject>Science archive</subject><subject>serum financial support</subject><issn>0001-527X</issn><issn>1734-154X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkMtKBDEQRYMoOI5uXfcP9JhHJT1ZiYgvEHSh4K6pJJU20pMe-jGgX2_ruHFTBfdcDkUxdi74Sqm1vUC3XUkuYSWkXNsDthCVglJoeDtkC865KLWs3o7ZyTB8cC6VsLBgu-eedthS9lR0sfCp91OLY8pNgXlMrguJhgIbTHkYi3faYNO008xT_umnHNuJ8hcWu9RPw1ydc9qmQJvki4Fw6HIxHyUu5iF_4HPXYg6n7ChiO9DZ316y19ubl-v78vHp7uH66rH0IORYEkQXdEUxOmODReIVKO68dAZCIInKVkhaRWOBg9IcIJIO3qyVINCgluxh7w0dftTbPm2w_6w7TPVv0PVNjf2YfEu1iZasQKkdEXjyjhO4Klowwhgx_3LJLveu7eQ2FDzlscf2n_Q_yem9brpdLQSvKqWN-gZI9YOp</recordid><startdate>20240219</startdate><enddate>20240219</enddate><creator>Kondratiuk, Katarzyna</creator><creator>Hallmann, Ewelina</creator><creator>Szymański, Karol</creator><creator>Łuniewska, Katarzyna</creator><creator>Poznańska, Anna</creator><creator>Brydak, Lidia B.</creator><general>Frontiers Media S.A</general><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240219</creationdate><title>Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland</title><author>Kondratiuk, Katarzyna ; Hallmann, Ewelina ; Szymański, Karol ; Łuniewska, Katarzyna ; Poznańska, Anna ; Brydak, Lidia B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-e4fbd57effb69d9ae07430bc2b64dde2a397ae53f6940435044fe5dc6831e4543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>GMT</topic><topic>hemagglutinin antibodies</topic><topic>influenza</topic><topic>protection rate</topic><topic>Science archive</topic><topic>serum financial support</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondratiuk, Katarzyna</creatorcontrib><creatorcontrib>Hallmann, Ewelina</creatorcontrib><creatorcontrib>Szymański, Karol</creatorcontrib><creatorcontrib>Łuniewska, Katarzyna</creatorcontrib><creatorcontrib>Poznańska, Anna</creatorcontrib><creatorcontrib>Brydak, Lidia B.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Acta Biochimica Polonica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondratiuk, Katarzyna</au><au>Hallmann, Ewelina</au><au>Szymański, Karol</au><au>Łuniewska, Katarzyna</au><au>Poznańska, Anna</au><au>Brydak, Lidia B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland</atitle><jtitle>Acta Biochimica Polonica</jtitle><date>2024-02-19</date><risdate>2024</risdate><volume>71</volume><issn>0001-527X</issn><eissn>1734-154X</eissn><abstract>The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14 years of age, 15–25 years of age, 26–44 years of age, 45–64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/abp.2024.12289</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0001-527X |
ispartof | Acta Biochimica Polonica, 2024-02, Vol.71 |
issn | 0001-527X 1734-154X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11077356 |
source | PubMed Central |
subjects | GMT hemagglutinin antibodies influenza protection rate Science archive serum financial support |
title | Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20circulating%20antibodies%20against%20hemagglutinin%20of%20influenza%20viruses%20in%20epidemic%20season%202021/2022%20in%20Poland&rft.jtitle=Acta%20Biochimica%20Polonica&rft.au=Kondratiuk,%20Katarzyna&rft.date=2024-02-19&rft.volume=71&rft.issn=0001-527X&rft.eissn=1734-154X&rft_id=info:doi/10.3389/abp.2024.12289&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_11077356%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-e4fbd57effb69d9ae07430bc2b64dde2a397ae53f6940435044fe5dc6831e4543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |